In a cancer gene therapy model recombinant adenoviruses challenge with wild-type tumor but not from challenges with expressing the herpes simplex virus thymidine kinase an unrelated syngeneic tumor cell line. Since cytotoxic T (HSVtk) gene were injected into tumors in situ, either alone lymphocyte responses in this tumor model were weak, we or in combination with adenoviruses (Avs) engineered to analyzed cytokine secretion from spleen cells of treated express IL-2, IL-6 or the costimulatory molecule B7-1.
Introduction
at the time of virus exposure. 4 One approach for cancer treatment using gene transfer Another approach for cancer treatment is the use of involves immune activation or enhancement employing suicide genes. 5 The best-studied suicide gene to date is genes for various cytokines or costimulatory molecules.
the gene encoding herpes simplex thymidine kinase Using retrovirus-mediated gene transfer, several groups (HSVtk) which converts the prodrug ganciclovir to a form have introduced cytokine genes ex vivo into murine that is cytotoxic for dividing cells and results in tumor cells, leading to secretion of the cytokine directly regression of solid tumors. [6] [7] [8] Critical for successful at the tumor site after implantation of cells. A surprisresults is the so-called 'bystander' effect that confers cytoingly large number of cytokines are able to induce a local toxicity to the neighboring nontransduced cells. 5 The response causing tumor rejection. 1 In addition, similar original studies were based on the use of retrovirus (Rv)-successful tumor rejections have been reported after mediated gene transfer. The HSVtk gene was delivered transgenic expression of the costimulatory B7-1 molecule via intratumoral injection of a retroviral packaging cell from tumor cells. 2, 3 line producing recombinant Rvs carrying the HSVtk gene While efficacious in gene transfer, this ex vivo approach into tumor cells to make them susceptible to subsequent is too cumbersome and technically demanding for rousystemic treatment with ganciclovir. This concept is curtine clinical application. Retroviral vectors are not well rently being tested clinically in protocols for the treatsuited for in vivo use because of their low titer, short halfment of human tumors. [9] [10] [11] [12] life at body temperature, sensitivity to inactivation by Recombinant Avs expressing cytokine genes have been human complement, and need for cellular division to used for ex vivo transduction of tumor cells and subpermit vector integration into the host cell genome. sequent tumor vaccination. 13 Many of these approaches Recombinant adenoviruses (Avs) on the other hand, can protect the animals against subsequent challenges by be produced at high titers, can express transgenes withtumorigenic doses of parental tumor cells inoculated at out integration in nondividing cells, and are therefore distant sites. Furthermore, recombinant Avs carrying suitable for direct gene transfer into a variety of cell types HSVtk have also been recently studied alone 14 or in combination with adenoviruses expressing cytokines. [15] [16] [17] We reasoned that a combination of the favorable features of the various gene transfer systems used in tumor treat-evaluated the efficacy of combining the tumoricidal effect dine incorporation of untransduced cells was unaffected.
Mixtures containing 15 and 2% transduced cells showed also clearly reduced 3 H-thymidine incorporation ( Figure  1) . When transduced at a MOI of 50 the bystander effect 2 × 10 9 infectious Avs expressing HSVtk, B7-1, IL-2, IL-6, showed a similar tendency but required about 10-fold or various combinations ( Figure 2 ). In situ transduction higher ganciclovir concentrations for similar effects (data with AvTK and subsequent ganciclovir treatment caused not shown).
tumor ablation in about 80% of the animals in repeated The expression of cytokines from AvIL-2-or AvIL-6-experiments. Combination treatment with AvTK/AvB7-transduced M-MSV tumor cells was examined by ELISA 1, AvTK/AvIL-2 or AvTK/AvIL-6 followed by ganciclo- (Table 1) . Expression was comparable with previous vir caused tumor rejection in only 40-60% of mice. Treatstudies using retroviral gene transfer. 18 Transduction ment with AvB7-1, AvIL-2 or AvIL-6, alone as well as efficiency with AvB7-1 was assayed by measuring any combination of these Avs caused tumor ablation only expression density of B7-1 on mouse M-MSV tumor cells occasionally. Mice injected with Avnull (no transgene) or by flow cytometry (Table 1) and was found to be in the AvTK without ganciclovir treatment did not result in same range as after transduction with B7-1 expressing tumor rejection. Rvs (unpublished observations).
Animals whose primary tumor was ablated using AvTK/ganciclovir or combinations with AvB7-1, AvIL-2 Treatment of established tumors with recombinant Avs or AvIL-6 were re-challenged by injection of 2 × 10 6 Mand challenge of cured animals with parental tumor In vitro evaluation of the antitumor CTL response Specific lysis of tumor target cells by spleen cells harvested from mice 4-6 weeks after Av treatment was measured in CTL assays for each mouse in the various treatment groups, whether or not tumor ablation occurred ( Figure 3 ). AvTK and AvTK/AvB7-1 plus ganciclovirtreated animals tended to show better specific lysis compared with AvTK/AvIL-2 and AvTK/AvIL-6 plus ganciclovir-treated as well as to Avnull-treated or untreated control mice. However, none of these differences was statistically significant. Spleen cells from animals treated with AvB7-1, AvIL-2 or AvIL-6 alone, as well as combinations of these Avs did not result in any clear CTL activity due to high individual variability within the animals in these groups (data not shown). Overall, in vitro CTL responses were weak and did not always correlate with tumor rejection. cytokine secretion pattern of mice 4-6 weeks after treat- In a further experiment, animals which had been cured from M-MSV tumors by different Av treatment cytokines under investigation included IL-2, IL-4, IL-6, GM-CSF and IFN␥. We first correlated the secretion of modalities were re-challenged with the parental M-MSV tumor cell line or an unrelated syngeneic tumor cell line, cytokines from Av-treated mice after re-stimulation of spleen cells in vitro with tumor cells. We found signifi-K-Balb. We also included control groups of animals which had been previously inoculated with irradiated Mcantly higher production of GM-CSF (600 ± 57 versus 219 ± 36 pg/ml; P Ͻ 0.0001), IFN␥ (16006 ± 3257 versus MSV tumor cells or viable M-MSV tumor cells stably expressing B7-1 molecules from Rv transduction. The 8523 ± 2087 pg/ml; P = 0.0492) and IL-2 (1343 ± 174 versus 824 ± 143 pg/ml; P = 0.0237) by splenocytes from mice mice in the AvTK, AvTK/AvB7-1 and AvTK/AvIL-2 groups, as well as the group of mice previously inocuwhich had rejected the tumor compared with splenocytes from mice failing to reject their tumors ( Figure 4 ) indelated with Rv-transduced M-MSV cells (M-MSVRvB7-1), were fully protected from a tumor challenge with parpendent of the treatment modality. By contrast, secretion of IL-4 (21.9 ± 4.7 versus 22.4 ± 4.7 pg/ml; P = 0.9489) and ental M-MSV tumor cells. However, wild-type M-MSV cells formed tumors in 50% of the animals previously IL-6 (2092 ± 157 versus 2231 ± 166 pg/ml; P = 0.5465) was comparable in all mice including normal unchallenged treated and cured of tumors with AvTK/AvIL-6; and in 40% of the animals pretreated with irradiated M-MSV mice. The cytokine secretion pattern was dependent only on the fact of tumor rejection whereas no significant difcells. The previously unseen K-Balb cells formed tumors in all mice. ferences in the cytokine secretion patterns between mice from groups pretreated with different combinations of In these re-challenged mice the cytokine secretion was examined 8-10 weeks after the initial treatment with therapeutic Avs could be observed. therapeutic Avs and 4-6 weeks after re-challenge ( Figure  5 ). We observed significantly lower secretion of GM-CSF In the same experimental setting, we correlated the production of IL-2, IL-4, IL-6, GM-CSF and IFN␥ with the Discussion specific lysis of tumor cells in vitro using splenocytes from animals which had been immunized by injection of In many studies immune modulatory molecules irradiated or B7-1 transgenic M-MSV cells or splenocytes expressed by tumor cells have been found to generate a derived from mice whose M-MSV primary tumor was systemic immune response specific for parental tumor ablated by AvTK/ganciclovir treatment. These animals cells and to protect the animals from a tumor challenge. were re-challenged with either M-MSV or K-Balb tumor By contrast, the development of a protective systemic cells. CTL-positive mice showed a significantly higher immune response after HSVtk/ganciclovir treatment has secretion of GM-CSF (P Ͻ 0.0001) and of IL-6 (P = 0.0002, been less well documented. In this study we investigated Figure 6 ). No difference in secretion of the other cytogene therapy strategies for the treatment of experimental tumors in mice employing the HSVtk/ganciclovir suicide kines was found. system. To improve the efficacy of gene transfer we delivered the transgenes by recombinant Avs rather than Rvs because of their superior transduction efficiency in vivo. Treatment with AvTK/ganciclovir cured about 80% of 
nations of Avs and re-challenged with M-MSV or K-Balb tumor cells
We further studied the effects of supplementation of shown to enable the immune system to reject B7-1 transpg/ml. genic tumors. 2,3 IL-2 is the major growth factor for T lymphocytes and was one of the first immune modulatory molecules studied in gene transfer experiments for tumor range. However, it is not possible to determine exactly transgene expression from tumor cells after intratumoral treatment. 4, 18 ,20 IL-6 participates in generating antitumor CTL responses 21 but has different and even opposite injection of AvIL-2 and thus to exclude the possibility of secretion of inhibitory amounts of IL-2 at the injection effects on tumor growth in gene transfer experiments. [22] [23] [24] [25] In our experiments no enhancement of the efficacy of site.
Previous observations in an Rv-based in vivo gene AvTK/ganciclovir-induced tumor ablation or modification of any of the immunological parameters measured transfer system for the treatment of brain tumors 27 are in agreement with our notion of an inhibitory effect of was observed; in fact, mice in the combination groups responded less favorably to the treatment. It has been combining AvTK/ganciclovir with AvIL2 on tumor rejection compared with AvTK/ganciclovir therapy. Howreported that IL-2 expressed from tumor cells as a cancer vaccine has a concentration optimum 26 above which ILever, other investigations demonstrated an improved treatment outcome for combined application of 2 has inhibitory effects on tumor rejection. In our experiments, in vitro IL-2 secretion was in this therapeutic AvTK/ganciclovir treatment and recombinant Avs expressing IL-2. [15] [16] [17] In contrast to our experiments, these spleen cells from K-Balb bearing mice, upon in vitro restimulation with M-MSV cells, would produce a cytokine previous studies were based on measurements of tumor diameters rather than animal survival, which in fact was secretion profile comparable with the mice re-challenged with M-MSV cells. The fact that they do not suggests that the same for AvTK/AvIL-2 in comparison with AvTK treatment.
GM-CSF secretion might be suppressed in tumor bearing mice. Expression of the B7-1 molecule enables the tumor cell to fulfill costimulatory functions which are normally In a successful antitumor immune response a predominance of Th1 cytokines would be expected. 19 We accomplished exclusively by professional antigenpresenting cells. M-MSV tumor cells readily express addressed this question by comparing the production of IFN␥ and IL-4, Th1 and Th2 cytokines, respectively, by MHC I molecules but lack expression of MHC II molecules (unpublished observations). Therefore, B7-1 gene spleen cells from mice which had rejected their tumor in comparison with mice failing to reject their tumors. Our transfer into M-MSV tumor cells has the potential to convert the tumor cell into an antigen presenting cell. Howfindings were in agreement with this hypothesis as we found increased levels of IFN␥ but not of IL-4 production ever, B7-1 interacts with two ligands: binding of B7-1 to constitutively expressed CD28 receptors transmits an upin cured mice compared with tumor bearing mice. However, it remains unexplained why IL-4 has been shown regulating signal in T lymphocytes, whereas B7-1 binding to CTLA4, which is expressed only upon T lymphocyte to generate antitumor immune responses in vivo when stably expressed from tumor cells 31 but is not produced activation, down-regulates activated T lymphocytes. 28 Consecutive binding to these two B7-1 receptors creates during an antitumor immune response. It is conceivable that immunogenic Av proteins cona feedback loop to control T lymphocyte activation. Thus it is conceivable, that the sum effect of constitutive tribute to tumor rejection. However, lack of tumor ablation after injection of Avnull or AvTK without ganexpression of B7-1 from transgenic tumor cells is T lymphocyte suppression which might explain the observed ciclovir treatment provides sufficient evidence to exclude the possibility of an immune response directed against inhibition of tumor rejection in our experiments.
The inhibitory effect of IL-6 on tumor rejection by Av proteins as the primary cause of tumor rejection. In summary, our results indicate that antitumor suicide AvTK/ganciclovir treatment remains, aside from the mentioned unclear effects on tumor growth in gene transtherapy with Avs engineered to express HSVtk followed by systemic ganciclovir treatment is efficient in rejection fer experiments, [22] [23] [24] [25] elusive. The antitumor immune response generated upon treatof experimental M-MSV tumors and for the induction of a protective antitumor immune response. In our experiment with recombinant Avs was investigated by re-challenging the mice with parental tumor cells, by CTL mental setting this tumor-ablative effect could not be amplified by co-application of Avs expressing B7-1 or the assays, and by measurement of cytokine secretion of spleen cells from the treated mice. Re-challenge of anicytokines IL-2 or IL-6. Sufficient antitumor immunity was primarily accompanied by the secretion of enhanced levmals demonstrated protection of all initially cured mice in the AvTK, AvTK/AvB7-1 and AvTK/AvIL-2 groups. els of GM-CSF from spleen cells of cured mice. Increased IFN␥ secretion and unchanged secretion of IL-4 from By contrast, only half of the re-challenged mice were protected from tumor growth in the AvTK/AvIL-6 group.
spleen cells of cured mice indicates the predominance of a Th1-mediated antitumor immune response. However, the CTL responses in our tumor model were weak and did not always correlate with in vivo results.
Among the cytokines which were secreted in increased
Materials and methods
amounts from mice that rejected their tumor, GM-CSF was the most reliable correlate of antitumor immunity. Cells Thus, it might be a useful parameter for the characterizThe adenoviral packaging cell line 293, 32 as well as the ation of a sufficient antitumor immune response. Premurine fibrosarcoma cell lines M-MSV-BALB/3T3 vious studies identified GM-CSF as a potent stimulator (designated M-MSV for the remainder of the paper) 33 and of a specific and long-lasting antitumor immunity 22 and K-Balb, 34 were obtained from ATCC (Gaithersburg, MD, documented its importance for the maturation of antigen USA). All cell lines were grown in Dulbecco's modified presenting cells into stimulators of T cell activation. 29 ILEagle's medium (DMEM) supplemented with 10% fetal 6, IL-2 and IFN␥ production from these mice was also bovine serum (FBS) and l-glutamine (all purchased from enhanced but was less reliable. The level of cytokine proLife Technologies, Grand Island, NY, USA). duction by spleen cells was independent from the treatment modality which caused tumor regression, and production of these cytokines might be directly related to Recombinant Avs Recombinant replication defective Avs expressing the protective immunity generated upon treatment of the primary tumor with the therapeutic vectors. murine B7-1, human IL-2, murine IL-6 or HSVtk were produced as described earlier. 32 Briefly, the transgenes However, it is comprehensible that the production of cytokines by spleen cells is causally related to whether were subcloned into the adenoviral shuttle plasmid pAVS6. 35 The resultant plasmids were cotransfected with the animal was tumor bearing at the time the spleen cells were harvested. Immune suppressive effects of bearing a an E1A/E1B and E3-deleted subgenomic fragment of DNA from Ad5 mutant dl327 (kindly provided by Dr T tumor have been described. 30 Evidence supporting this comes from the observation that mice cured from M-MSV Shenk, Princeton University) by Ca-phosphate precipitation technique into the E1A/E1B expressing 293 cell tumors showed low secretion of cytokines when challenged with K-Balb cells ( Figure 5 ). If treatment of the line, 32 which is permissive for replication of E1A/E1B defective Avs. Recombinant Avs can be obtained in this primary tumor were responsible for generating protective immunity against M-MSV, it would be expected that system by homologous recombination events between the adenoviral sequences in pAVS6. The transfected 293 10 and 100 m) for 24 h. During the last 6 h of the assay, tritiated ( Cell staining was performed following standard pro-(Amersham) was added for 1 h to label the cells. After labeling the cells were washed four times, adjusted to cedures. Briefly, cells were harvested by trypsinisation, trypsin was inactivated with serum, and the cells were 50 000/ml, and 100 l of this cell suspension was pipetted into the appropriate number of wells on a 96-well round washed in phosphate-buffered saline (PBS) containing 2% bovine serum albumin (BSA). Antibody was added bottom plate (Costar). The prestimulated mouse spleen cells were collected, washed once, and adjusted to the to a final concentration of 1 g/ml, incubated at room temperature for 30 min and washed once in PBS/BSA. respective cell number in order to obtain effector:target ratios of 100:1, 33:1, 11:1 and 3.3:1. Additional wells were The cell pellet was resuspended in 500 l PBS supplemented with 1 g/ml ethidium bromide. The relative set up for determination of spontaneous and maximum release (the latter by lysing the cells in 0.8% Triton Xfluorescence intensity of labeled cells was measured on a FACScan flow cytometer (Becton Dickinson, San Jose, 100) of 51 Cr from tumor cells. After 4 h incubation the supernatants were harvested and counted in a ␥-counter CA, USA).
(ICN). Results were calculated as the percentage specific lysis by the formula: % Lysis = (Experimental Counts − Expression of IL-2 and IL-6 from AvIL-2 and AvIL-6-transduced tumor cells Spontaneous Release) × 100/(Maximum Release − Spontaneous Release). One million M-MSV tumor cells were transduced in a sixwell tissue culture plate and cultured for 24 h in 1 ml growth medium. The amount of cytokine secreted into Quantification of cytokines secreted from mouse spleen cells the medium was determined by enzyme-linked immunosorbent assay (ELISA; Endogen, Boston, MA, USA). The Spleen cells from mice were harvested in the same manner as described for the CTL assays. They were stimuresults were calculated as pg cytokine/24 h/10 6 cells. 
